Terns Pharmaceuticals, Inc. (TERN)

USD 5.76

(-15.29%)

Market Cap (In USD)

489.24 Million

Revenue (In USD)

-

Net Income (In USD)

-90.21 Million

Avg. Volume

1.96 Million

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
4.32-11.4
PE
-
EPS
-
Beta Value
-0.334
ISIN
US8808811074
CUSIP
880881107
CIK
1831363
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Ms. Amy L. Burroughs M.B.A.
Employee Count
-
Website
https://www.ternspharma.com
Ipo Date
2021-02-05
Details
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.